Influenza Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, (MMRIIÒ) and Varicella (VARIVAXÒ) Vaccines Administered Concurrently to Healthy Children (AV018)
Verified date | February 2008 |
Source | MedImmune LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
- To compare immune responses to measles, mumps, rubella, and varicella antigens
following vaccination in children who receive FluMist concurrently with MMRIIÒ and
VARIVAXÒ and in children who receive an intranasal placebo mist concurrently with
MMRIIÒ and VARIVAXÒ (Group 2 vs. Group 1).
- To compare immune responses to the three strains of influenza (H1N1, H3N2, and B)
following a two dose regimen of FluMist in children who receive the initial FluMist
dose concurrently with MMRIIÒ and VARIVAXÒ and in children who receive two doses of
FluMist alone (Group 2 vs. Group 3).Secondary:
- To assess the safety and tolerability of concurrent administration of FluMist with
MMRIIÒ and VARIVAXÒ.
Status | Completed |
Enrollment | 1200 |
Est. completion date | December 2003 |
Est. primary completion date | September 2003 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 12 Months to 15 Months |
Eligibility |
Inclusion Criteria: - 12 to 15 months of age (not reached their 16th month birthday); - In good health; - Parent/guardian available by telephone or for home visits; - Ability of the parent/guardian to understand and comply with the requirements of the protocol; - Signed informed consent by parent/guardian; and - Up to date with the primary series of recommended vaccines per standard clinic practice and local vaccine availability. Exclusion Criteria: - Previous known measles, mumps, rubella or varicella disease; - Previous vaccination against measles, mumps, rubella or varicella disease; - Hypersensitivity to egg or egg protein; - Signs or symptoms of any immunosuppressive or immune deficiency disease or ongoing immunosuppressive therapy; or an immunosuppressed individual living in the same household; - Acute febrile (>100.0oF [37.8°C] oral) illness or clinically significant upper respiratory illness within the 72 hours prior to enrollment; - Use of aspirin (acetylsalicylic acid) or aspirin-containing products in the month prior to enrollment, or expected use of aspirin while enrolled in this study; - Administration of any intranasal medication within two weeks prior to enrollment or expected receipt during this study; - Administration of any live virus vaccine within one month prior to enrollment through 30 days after Visit 3; - Administration of any inactivated vaccine within two weeks prior to enrollment through 30 days after Visit 3; - Participation in another investigational trial within one month prior to enrollment or expected enrollment in another investigational trial during this study; - Receipt of any blood product within three months prior to vaccination or expected receipt within the study duration; and - Any condition which, in the opinion of the investigator, would interfere with the interpretation or evaluation of the vaccines. - History of two or more episodes of medically attended wheezing illness by parent/guardian report. - History of medically attended wheezing illness or bronchodilator medication use within four weeks of enrollment by parent/guardian report. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
MedImmune LLC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children | Day 42 | No | |
Secondary | Compare immune responses to the three strains of influenza (H1N1, H3N2, and B) following a two dose regimen of FluMist in children who receive the initial FluMist | Day 42 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |